TickerFacts.

A business in context

VXRT research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-08-21 · 0001437749-26-028916 · Items 8.01

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001437749-26-026289

  3. 8-K · Current report

    Report date 2026-08-06 · 0001437749-26-026280 · Items 2.02,9.01

  4. 8-K · Current report

    Report date 2026-07-27 · 0001437749-26-024560 · Items 8.01

  5. 4 · Ownership change

    Report date 2026-07-16 · 0001437749-26-023863

  6. 4 · Ownership change

    Report date 2026-07-16 · 0001437749-26-023810

  7. 4 · Ownership change

    Report date 2026-07-16 · 0001437749-26-023809

  8. 4 · Ownership change

    Report date 2026-07-16 · 0001437749-26-023808

  9. 4 · Ownership change

    Report date 2026-07-16 · 0001437749-26-023807

  10. 8-K · Current report

    Report date 2026-07-16 · 0001437749-26-023762 · Items 5.07,7.01,9.01

  11. 8-K · Current report

    Report date 2026-07-06 · 0001437749-26-022876 · Items 8.01,9.01

  12. 8-K · Current report

    Report date 2026-07-01 · 0001213900-26-074576 · Items 1.01,7.01,9.01

  13. 8-K · Current report

    Report date 2026-06-22 · 0001437749-26-021833 · Items 1.01,8.01,9.01

  14. 4 · Ownership change

    Report date 2026-05-22 · 0001437749-26-018385

  15. 4 · Ownership change

    Report date 2026-05-19 · 0001437749-26-018117

  16. 8-K · Current report

    Report date 2026-05-19 · 0001213900-26-059127 · Items 8.01,9.01

  17. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001437749-26-015608

  18. 8-K · Current report

    Report date 2026-05-07 · 0001437749-26-015586 · Items 2.02,9.01

  19. 4 · Ownership change

    Report date 2026-04-23 · 0001437749-26-014528

  20. 10-K/A · Annual report

    Report date 2025-12-31 · 0001437749-26-014245

  21. 8-K · Current report

    Report date 2026-04-23 · 0001437749-26-013195 · Items 5.02,7.01,9.01

  22. 8-K · Current report

    Report date 2026-04-20 · 0001437749-26-012882 · Items 8.01

  23. 8-K · Current report

    Report date 2026-04-16 · 0001437749-26-012623 · Items 1.01,3.02,7.01,9.01

  24. 10-K · Annual report

    Report date 2025-12-31 · 0001437749-26-008023

  25. 8-K · Current report

    Report date 2026-03-12 · 0001437749-26-007968 · Items 2.02,9.01

  26. 8-K · Current report

    Report date 2025-12-18 · 0001437749-25-038774 · Items 1.02

  27. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001437749-25-034840

  28. 8-K · Current report

    Report date 2025-11-13 · 0001437749-25-034829 · Items 2.02,9.01

  29. 8-K · Current report

    Report date 2025-11-04 · 0001437749-25-033362 · Items 1.01,7.01,9.01

  30. 8-K · Current report

    Report date 2025-10-08 · 0001437749-25-030868 · Items 7.01

  31. 8-K · Current report

    Report date 2025-09-19 · 0001437749-25-029485 · Items 3.01

  32. 8-K · Current report

    Report date 2025-09-18 · 0001437749-25-029434 · Items 8.01

  33. 8-K · Current report

    Report date 2025-09-05 · 0001437749-25-028570 · Items 5.07,7.01,9.01

  34. 8-K · Current report

    Report date 2025-09-02 · 0001437749-25-028167 · Items 5.02,7.01,9.01

  35. 8-K · Current report

    Report date 2025-08-27 · 0001437749-25-028047 · Items 7.01,8.01,9.01

  36. 8-K · Current report

    Report date 2025-08-20 · 0001437749-25-027524 · Items 7.01,9.01

  37. 8-K · Current report

    Report date 2025-08-14 · 0001437749-25-027110 · Items 7.01,9.01

  38. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001437749-25-026514

  39. 8-K · Current report

    Report date 2025-08-13 · 0001437749-25-026511 · Items 2.02,9.01

  40. DEF 14A · Proxy statement

    Report date 2025-09-05 · 0001437749-25-025111

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 1 transaction rows1PSale: 0 transaction rows0SGrant / award: 2 transaction rows2AExercise / conversion: 0 transaction rows0MTax / exercise payment: 1 transaction rows1FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

4 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-05-22
2026-05-26
Watson W. MarkP · Purchase
Acquired
Common Stock10000.00.65
2026-05-19
2026-05-21
Grasman Jeroen NicolaasF · Tax / exercise payment
Disposed
Common Stock31395.00.61
2026-04-23
2026-05-01
BREITMEYER JAMES BA · Grant / award
Acquired
Common Stock78800.00.0
2026-04-23
2026-05-01
BREITMEYER JAMES BA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
157400.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000072444Vaxart, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Vaxart · alias · wikidata
  • Aviragen Therapeutics, Inc. · former SEC name · 2016-04-26 to 2018-02-15
  • Biota Pharmaceuticals, Inc. · former SEC name · 2012-11-14 to 2016-04-13
  • NABI BIOPHARMACEUTICALS · former SEC name · 2010-07-21 to 2012-11-08
  • NABI BIOPHARMACEUTICALS · former SEC name · 2002-04-15 to 2010-06-29
  • NABI /DE/ · former SEC name · 1996-11-27 to 2002-02-14
  • NORTH AMERICAN BIOLOGICALS INC · former SEC name · 1994-11-08 to 1996-02-14
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$28.70M$30.55M
2023-12-31$7.38M$8.09M
2018-12-31$4.16M$5.53M
2017-12-31$5.84M$7.95M

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗